<DOC>
	<DOC>NCT00646932</DOC>
	<brief_summary>The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure.</brief_summary>
	<brief_title>Paricalcitol Injection Phase II Trial</brief_title>
	<detailed_description>The purpose of this study is pharmacokinetic &amp; tolerability.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure Subject is considered by investigator, for any reason, to be an unsuitable candidate for the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>